$CHEK Megathread.

I want to do DD on a low penny stock which may soon blossom into a beautiful, NASDAQ compliable stock for you. This being a biotech stock, I want to keep things as simple as possible for everyone and I'll do my best to explain my thoughts as we go. Enjoy :))

— Dan Holy (@dantheholy) July 14, 2020

Ok, so promising so far. This is essentially a new form of a colonoscopy which removes many of the obstacles preventing people from having an original colonoscopy (eg: fear…)

Before I go further into the product, let's talk more about who Check-Cap Ltd are…

— Dan Holy (@dantheholy) July 14, 2020

-Their vision since inception was to create an ingestible colorectal cancer screener.

-They have offices in Israel and Boston MA.

So, we have some encouraging signs already as to this company's motives and reputation.

Onwards we go…

— Dan Holy (@dantheholy) July 14, 2020

-Ovadia has a BSc in Electrical Engineering from the Technion Institute in Haifa, Israel.

Well, we have an established CEO with a good track record. He also seems to have a decent amount of competence. More hopeful signs!

— Dan Holy (@dantheholy) July 14, 2020

-Hanley is also experienced in introducing numerous drugs and medical devices to places such as Eastern Europe, China, Latin America…

Again, looks good. Competence surrounding the leadership is high. Also, Hanley seems to have a keen eye for emerging markets, a good sign here

— Dan Holy (@dantheholy) July 14, 2020

Ok, now onto the product – C-Scan. They have spotted a gap in the market, here's why:

-Colorectal cancer (CRC) = 3rd most common cancer diagnosed in men and women.

-CRC = 2nd leading cause of cancer related deaths.

Essentially, this product screens for a very common cancer.

— Dan Holy (@dantheholy) July 14, 2020

-Imo, and in the opinion of medical experts, regular screening should take place for 50-75 year olds

-HOWEVER, current screening methods are unattractive.

Here is a graphic demonstrating what people say puts them off getting a screening rn

Imo, $CHEK could fill a huge gap here pic.twitter.com/zp8x0YtaH7

— Dan Holy (@dantheholy) July 14, 2020

C-Scan is needed because it means:

-No fasting or bowel prep pre colonoscopy
-Patient can continue w/ normal daily activities while capsule is inside
-Capsule naturally propelled through large intestine by body
-Data collection is unobtrusive

Why is this so groundbreaking? …

— Dan Holy (@dantheholy) July 14, 2020

-The capsule will simply be excreted and the patient is notified once it's left the body 🙂

On to C-scan Track:

-As the pic showed, it's 3 patches worn on the back during cap passage.

-This simply records the data

So far so good then. The fear of a colonoscopy has gone! Yay!

— Dan Holy (@dantheholy) July 14, 2020

Financials:

-Need to regain compliance by 28th Dec 2020 according to 5th June PR.

-27th May PR stated that the company had strengthened their balance sheet through $16.3m in direct offerings & a private placement of shares.

-Looking to start US C-Scan trials in 2021.

— Dan Holy (@dantheholy) July 14, 2020

Risks:

-Seem to have used direct offerings as a means of funding. If this continues, we may see a lower price.

-FDA IDE approval not yet received.

-Stock seems to be being manipulated atm due to it's very low levels. However I do see this as a good entry point.

— Dan Holy (@dantheholy) July 14, 2020

Chart:

-The time is ripe to buy.

-Low RSI & potential MACD cross.

-Volume is coming in.

-50 Day MA infers a PT of $1 to $1.5 in the near future. pic.twitter.com/YgV2QRAcvj

— Dan Holy (@dantheholy) July 14, 2020

Wowowow! Another long one 🙂 Hope you've gained some useful info on this one. I really enjoyed making this DD. Yeah, a good all round aim here. Hope they get this thing going and do well. Anways, hope you all enjoyed this one! See you for the next one :)) $KTOV $MRK $MARK $BNGO

— Dan Holy (@dantheholy) July 14, 2020

⬇ ⬇ ⬇ What do you think of this DD? Leave a rating below!